Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Publication year range
1.
Org Biomol Chem ; 13(1): 142-56, 2015 Jan 07.
Article in English | MEDLINE | ID: mdl-25348733

ABSTRACT

MMP-2 is a validated target for the development of anticancer agents. Herein we describe the synthesis of a new series of potent phenylalanine derived hydroxamates, with increased MMP-2/MMP-9 selectivity compared to analogous hydroxamates described previously. Docking and molecular dynamics experiments have been used to account for this selectivity, and to clarify the role of the triazole ring in the binding process.


Subject(s)
Drug Design , Gelatinases/antagonists & inhibitors , Hydroxamic Acids/chemical synthesis , Hydroxamic Acids/pharmacology , Matrix Metalloproteinase Inhibitors/chemical synthesis , Matrix Metalloproteinase Inhibitors/pharmacology , Chemistry Techniques, Synthetic , Gelatinases/chemistry , Gelatinases/metabolism , Hydroxamic Acids/chemistry , Hydroxamic Acids/metabolism , Matrix Metalloproteinase Inhibitors/chemistry , Matrix Metalloproteinase Inhibitors/metabolism , Molecular Docking Simulation , Molecular Dynamics Simulation , Phenylalanine/chemistry , Substrate Specificity , Triazoles/chemistry
2.
Chembiochem ; 15(13): 1873-6, 2014 Sep 05.
Article in English | MEDLINE | ID: mdl-25044410

ABSTRACT

Matrix metalloproteinase 2 (MMP-2) is involved in cancer development and is overexpressed in a variety of malignant tumors. MMP-2 activity is controlled mainly by transcription, proteolytic activation, and inhibition by endogenous inhibitors. It had previously been demonstrated that MMP-2 activity is also regulated by phosphorylation at several sites by protein kinase C. Here we demonstrate, by means of bioinformatics and biochemical and cellular assays, that protein kinase CK2 also acts as a modulator of MMP-2 activity. CK2 down-regulates MMP-2 in vitro, and inhibition of CK2 in human fibrosarcoma cells results in up-regulation of MMP-2. The discovery of the crosstalk between MMP-2 and CK2 opens the possibility of new combined anticancer therapies.


Subject(s)
Casein Kinase II/metabolism , Casein Kinase II/pharmacology , Matrix Metalloproteinase 2/metabolism , Matrix Metalloproteinase Inhibitors/pharmacology , Cell Line, Tumor , Computational Biology , Down-Regulation/drug effects , Fibrosarcoma/metabolism , Humans , Phosphorylation , Receptor Cross-Talk/drug effects
3.
Chembiochem ; 15(3): 399-412, 2014 Feb 10.
Article in English | MEDLINE | ID: mdl-24449516

ABSTRACT

Looking for water-soluble inhibitors of matrix metalloproteinase-2 (MMP-2 or gelatinase A), we have previously reported compound 1, a potent MMP-2 inhibitor with a promising selectivity over the structurally homologous MMP-9 (gelatinase B). Here we report the results of Molecular Dynamics (MD) simulations for both gelatinases (MMP-2 and MMP-9), and for the corresponding MMP/1 complexes, in an attempt to shed light on the observed selectivity between the two enzymes. These studies indicated a higher plasticity of MMP-2 at the S1' pocket and suggested an induced-fit effect at the "back door" of this pocket. On the basis of these observations, we designed 11 a-d to aid further discrimination between MMP-2 and MMP-9. Those compounds displayed notably lower inhibitory activities against MMP-9; in particular, 11 b proved to be over 100 times more active against MMP-2 than against MMP-9. MD simulations of the MMP/11 b complexes and thermodynamic integration calculations provided structural insight and relative binding energies consistent with the experimentally observed activity data. These findings demonstrate that structural differences in the S1' pocket bottom permit an improvement in selectivity in the inhibition of MMP-2 over that of MMP-9; this is of great relevance for future structure-based drug design because MMP-2 is a validated target for cancer therapy, whereas MMP-9 plays both detrimental and protective roles in cancer. This study also supports the need to consider the dynamics of the S1' pocket in order to achieve selectivity in the inhibition of MMPs.


Subject(s)
Matrix Metalloproteinase 2/chemistry , Matrix Metalloproteinase Inhibitors/chemistry , Molecular Dynamics Simulation , Sulfones/chemistry , Binding Sites , Catalytic Domain , Drug Design , Hydroxamic Acids/chemical synthesis , Hydroxamic Acids/chemistry , Hydroxamic Acids/metabolism , Matrix Metalloproteinase 2/metabolism , Matrix Metalloproteinase 9/chemistry , Matrix Metalloproteinase 9/metabolism , Matrix Metalloproteinase Inhibitors/chemical synthesis , Matrix Metalloproteinase Inhibitors/metabolism , Protein Binding , Structure-Activity Relationship , Sulfones/chemical synthesis , Sulfones/metabolism , Thermodynamics
4.
Food Funct ; 5(2): 381-9, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24413695

ABSTRACT

Gallic acid and anthocyanins are abundant plant food bioactives present in many fruits and vegetables, being especially important in the composition of berries. Gallic acid has been shown to possess cytotoxic properties in several cancer cell lines and to inhibit carcinogenesis in animal models. However, its mechanism of action is not yet fully understood. The aim of this study was to elucidate whether the observed inhibitory activity of gallic acid against gelatinases corresponds to its cytotoxic activity in HT1080 cells and to determine if anthocyanins could exhibit a similar behavior. Gallic acid and delphinidin-3-glucoside have shown selective cytotoxicity towards HT1080 cells. Further analysis by a migration and invasion assay showed anti-invasive activities of gallic acid, delphinidin and pelargonidin-3-glucosides. Zymographic analysis demonstrated the inhibitory activity of gallic acid at the level of secreted and activated gelatinases. Moreover, gallic acid inhibited MMP-2 and MMP-9 proteolytic activity with very similar potency. NMR and molecular modelling experiments confirmed the interaction of gallic acid with MMP-2, and suggested that it takes place within the catalytic center. In this work we give some new experimental data supporting the role of these compounds in the inhibition of metalloproteases as the mechanism for their cytotoxic activity against fibrosarcoma.


Subject(s)
Anthocyanins/pharmacology , Antineoplastic Agents/pharmacology , Fibrosarcoma/drug therapy , Gallic Acid/pharmacology , Anthocyanins/chemistry , Antineoplastic Agents/chemistry , Binding Sites , Cell Line, Tumor , Cell Survival/drug effects , Dietary Supplements/analysis , Fibrosarcoma/enzymology , Fibrosarcoma/physiopathology , Gallic Acid/chemistry , Humans , Matrix Metalloproteinase 2/chemistry , Matrix Metalloproteinase 2/metabolism , Matrix Metalloproteinase 9/chemistry , Matrix Metalloproteinase 9/metabolism , Matrix Metalloproteinase Inhibitors/chemistry , Matrix Metalloproteinase Inhibitors/pharmacology , Models, Biological , Models, Molecular
5.
Org Biomol Chem ; 11(38): 6623-41, 2013 Oct 14.
Article in English | MEDLINE | ID: mdl-23989288

ABSTRACT

Water solubility is a key aspect that needs to be addressed to obtain drug-like compounds. In an effort to improve the water solubility of our recently reported nanomolar matrix metalloproteinase type 2 (MMP-2) inhibitors based on triazole-substituted hydroxamates, we synthesized a new series of α-sulfone, α-tetrahydropyran and α-piperidine, α-sulfone clicked hydroxamates and determined their inhibitory activities against both MMP-2 and MMP-9. The best results were found for 13e, a water-soluble compound that displays a low nanomolar activity against MMP-2 and is 26-fold less active against MMP-9. This finding allowed us to pursue in vitro permeability through the Caco-2 monolayer and opened the possibility of carrying out further preclinical investigations. Docking and MD simulations have been performed in order to rationalize the biological results. The inhibitory activity of this compound against a panel of ten MMPs was determined showing an interesting MMP-2/MMP-1, -8, and -14 selectivity profile. The cytotoxicity and anti-invasive activity of the compounds on highly metastatic human fibrosarcoma tumor cells (HT1080) were determined, showing, at 10 µM concentration, a decrease in cell invasiveness up to 80%.


Subject(s)
Antineoplastic Agents/pharmacology , Matrix Metalloproteinase 2/metabolism , Matrix Metalloproteinase Inhibitors/pharmacology , Triazoles/pharmacology , Water/chemistry , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/chemistry , Cell Line, Tumor , Cell Proliferation/drug effects , Dose-Response Relationship, Drug , Drug Screening Assays, Antitumor , Humans , Matrix Metalloproteinase Inhibitors/chemical synthesis , Matrix Metalloproteinase Inhibitors/chemistry , Models, Molecular , Molecular Structure , Quantum Theory , Solubility , Structure-Activity Relationship , Triazoles/chemical synthesis , Triazoles/chemistry
6.
Org Biomol Chem ; 10(36): 7334-46, 2012 Sep 28.
Article in English | MEDLINE | ID: mdl-22847655

ABSTRACT

Based on the benzo[b]naphtho[1,2-d]furan and benzo[b]naphtho[1,2-d]thiophene frameworks, a series of ligands with different basic side chains (BSCs) has been synthesized and pharmacologically evaluated. Also, their binding modes have been modelled using docking techniques. It was found that the introduction of a BSC in these systems brings about a decrease of affinity for both estrogen receptors α and ß in an in vitro competitive binding assay. However, two full antagonists of the estrogen receptor ß (9c and 9f) have been discovered, with potency in the low micromolar concentration in a cell-based luciferase reporter assay, and completely devoid of activity against the α receptor at the same concentration range. Differences in the ERα/ERß binding modes have also been rationalized with the help of molecular modelling techniques. This interesting functional profile could be used to elucidate the physiological role of each ER subtype.


Subject(s)
Antineoplastic Agents/pharmacology , Benzofurans/pharmacology , Naphthalenes/pharmacology , Receptors, Estrogen/antagonists & inhibitors , Thiophenes/pharmacology , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/chemistry , Benzofurans/chemical synthesis , Benzofurans/chemistry , Cell Proliferation/drug effects , Dose-Response Relationship, Drug , Drug Screening Assays, Antitumor , Humans , Ligands , MCF-7 Cells , Naphthalenes/chemical synthesis , Naphthalenes/chemistry , Structure-Activity Relationship , Thiophenes/chemical synthesis , Thiophenes/chemistry
7.
An. R. Acad. Farm ; 77(4): 99-117, oct.-dic. 2011. tab, ilus
Article in Spanish | IBECS | ID: ibc-96170

ABSTRACT

Siguiendo una estrategia de diseño basado en fragmentos, se describe la síntesis de una nueva serie de inhibidores de MMP-2. Para ello, se parte de un fragmento que contiene simultáneamente un grupo hidroxamato como Zinc Binding Group (ZBG) y un grupo azida. Esta subunidad se conecta mediante química “click" con otros fragmentos lipófilos que contienen un alquino terminal y que han sido seleccionados para interaccionar de manera selectiva con el subsitio S1’ de la MMP-2. Los compuestos sintetizados más activos, 20 y 21, presentan una alta potencia inhibitoria en MMP-2. Además, el compuesto 20 presenta un prometedor perfil de selectividad frente a algunas metaloproteasas consideradas anti-diana en cáncer, como MMP-8 y MMP-9(AU)


A new series of selective MMP-2 inhibitors is described, following a fragment-based drug design approach. A fragment containing an azide group and a well known hydroxamate ZBG, was synthesized. A click chemistry reaction was used to connect the azide to lipophilic alkynes selected to interact selectively with the S1’ subunit of MMP-2. The most active compounds, 20 and 21, displayed high values of IC50 against MMP-2. In addition, compound 20 has shown also a promissing selectivity profile against some antitarget metalloproteinases in cancer, such as MMP-8, and MMP-9(AU)


Subject(s)
Humans , Tissue Inhibitor of Metalloproteinases/chemistry , Matrix Metalloproteinases/antagonists & inhibitors , Drug Design , Drug Evaluation/methods , Antineoplastic Agents/chemistry
8.
Org Biomol Chem ; 9(12): 4587-99, 2011 Jun 21.
Article in English | MEDLINE | ID: mdl-21552627

ABSTRACT

A new series of MMP2 inhibitors is described, following a fragment-based drug design approach. One fragment containing an azide group and a well known hydroxamate Zinc Binding Group in a α-sulfone, α-tetrahydropyrane scaffold, has been synthesized. Water-LOGSY, STD and competition-STD experiments indicate that this fragment binds to the active site of the enzyme. A click chemistry reaction was used to connect the azide to lipophilic alkynes selected to interact selectively with the S1' subunit of MMP2, as shown by docking and molecular dynamic experiments of the designed compounds. The most potent compounds 18 and 19 displayed an IC(50) of 1.4 and 0.3 nM against MMP2 respectively, and showed negligible activity towards MMP1 and MMP7, two metalloproteinases which have a shallow S1' subsite. Compound 18 also showed a promising selectivity profile against some antitarget metalloproteinases, such as MMP8, and considerably less activity against MMP14 (IC(50) = 65 nM), and MMP9 (IC(50) = 98 nM), other MMPs characterized by having a deep S1' pocket and, therefore, more similar to MMP2.


Subject(s)
Antineoplastic Agents/chemical synthesis , Chemistry, Pharmaceutical , Hydroxamic Acids/chemical synthesis , Matrix Metalloproteinase Inhibitors , Protease Inhibitors/chemical synthesis , Antineoplastic Agents/pharmacology , Azides/chemistry , Binding Sites , Click Chemistry , Crystallography, X-Ray , Drug Design , Humans , Hydroxamic Acids/pharmacology , Inhibitory Concentration 50 , Matrix Metalloproteinase 1/metabolism , Matrix Metalloproteinase 2/metabolism , Matrix Metalloproteinase 7/metabolism , Models, Molecular , Neoplasms/drug therapy , Protease Inhibitors/pharmacology , Protein Binding , Structure-Activity Relationship , Substrate Specificity , Sulfones/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...